Canadian court supports Excedrin headache superiority claims over Tylenol.
This article was originally published in The Tan Sheet
Executive Summary
EXCEDRIN HEADACHE SUPERIORITY AD CLAIMS OVER TYLENOL are supported in a recent decision by the Ontario Court of Justice in Toronto. On July 25, Judge Donald Taliano denied a McNeil Consumer Products motion for an interlocutory injunction restraining Bristol-Myers Squibb from making statements and distributing ads that claim Excedrin is superior to Tylenol for headache or other pain relief because it contains caffeine.